US Patent

US7803838 — Compositions comprising nebivolol

Formulation · Assigned to Forest Laboratories Holdings ULC · Expires 2026-08-29 · 0y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition that combines nebivolol with at least one other cardiovascular agent.

USPTO Abstract

Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

Drugs covered by this patent

Patent Metadata

Patent number: US7803838
Jurisdiction: US
Classification: Formulation
Expires: 2026-08-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Forest Laboratories Holdings ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.